Investor Update

Basel, 19 December 2018

Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumors

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.